Aug 11, 2026 09:18AM
Jul 30, 2026 07:25AM
May 19, 2026 07:25AM
May 19, 2026 07:25AM
May 11, 2026 07:25AM
May 11, 2026 07:25AM
Apr 30, 2026 07:25AM Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Apr 27, 2026 07:25AM
Apr 27, 2026 07:25AM
Apr 22, 2026 07:25AM
Apr 22, 2026 07:25AM
Apr 15, 2026 07:25AM
Jan 30, 2026 07:25AM
May 7, 2025 08:16AM Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Mar 26, 2024 10:25AM
Mar 26, 2024 10:25AM
Aug 15, 2023 07:25AM
Aug 15, 2023 07:25AM
Jul 26, 2023 07:25AM
Jul 26, 2023 07:25AM
Apr 26, 2023 07:25AM Alterity Therapeutics (ATHE) Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
Apr 26, 2023 07:25AM
Apr 4, 2023 07:25AM
Mar 16, 2023 07:25AM
Mar 8, 2023 07:25AM
Feb 16, 2023 04:46PM
Feb 16, 2023 04:44PM
Jan 30, 2023 07:29AM Alterity Therapeutics' (ATHE) ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Jan 30, 2023 07:25AM
Jan 25, 2023 07:26AM
Jan 25, 2023 07:25AM
Jan 9, 2023 10:26AM
Jan 9, 2023 10:25AM
Nov 7, 2022 10:26AM
Nov 7, 2022 10:25AM Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
Oct 28, 2022 07:25AM
Oct 26, 2022 07:25AM
Oct 13, 2022 10:27AM
Oct 13, 2022 10:25AM
Sep 26, 2022 07:25AM
Sep 26, 2022 07:25AM
Sep 20, 2022 07:26AM Alterity Therapeutics (ATHE) Granted FDA Approval for NDA for ATH434
Sep 20, 2022 07:25AM
Aug 25, 2022 07:25AM
Jul 22, 2022 07:25AM
Jul 6, 2022 11:00AM
Jun 23, 2022 11:00AM
Jun 2, 2022 08:00AM
Apr 27, 2022 07:41AM Alterity Therapeutics (ATHE) Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
Apr 27, 2022 07:40AM

328,147 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All